Search results for " Rating"

showing 10 items of 529 documents

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

2000

Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.

AdultMalemedicine.medical_specialtyPsychosismedicine.medical_treatmentSigma receptorPanamesineDrug Administration ScheduleBasal Ganglia DiseasesPiperidinesInternal medicinemental disordersmedicineHumansReceptors sigmaAntipsychoticOxazolesBiological PsychiatryBiotransformationAgedPsychiatric Status Rating ScalesDose-Response Relationship DrugMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthEndocrinologyTreatment OutcomeTolerabilityDopamine receptorSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychiatry research
researchProduct

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.

2009

Abstract Background: To assess criteria and to identify predictive factors for functional outcome. The criteria should cover all domains proposed by the Remission in Schizophrenia Working Group. Method: PANSS ratings were used to evaluate the symptomatic treatment outcome of 262 inpatients with schizophrenia spectrum disorders within a naturalistic multicenter trial. Functional remission was defined as a GAF score > 61 (Global Assessment of Functioning Scale), SOFAS score > 61 (Social and Occupational Functioning Scale) and a SF-36 mental health subscore > 40 (Medical Outcomes Study—Short Form Health Survey). Multivariate logistic regression and CART analyses were used to determine valid cl…

AdultMalemedicine.medical_specialtySF-36Global Assessment of FunctioningNeuropsychological TestsLogistic regressionSeverity of Illness IndexDevelopmental psychology03 medical and health sciencesYoung Adult0302 clinical medicinePredictive Value of TestsRecurrenceInternal medicineMulticenter trialSeverity of illnessOutcome Assessment Health CaremedicineHumansBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesMiddle Agedmedicine.disease030227 psychiatry3. Good healthPsychiatry and Mental healthPsychotic DisordersROC CurveSchizophreniaPredictive value of testsSchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychologyPsychosocial030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia research
researchProduct

The Panic-Associated Symptom Scale: measuring the severity of panic disorder.

1991

The Panic-Associated Symptom Scale (PASS) is presented as a new measurement of the severity of the core symptoms of panic disorder. This first description addresses the rationale for its design and its scoring, score distributions, test-retest reliability, correlations within the PASS and with other scales, principal component structure, and response to drug therapy. Data are presented from a large study group of patients with panic disorder (n = 1168). Problems in measuring panic disorder are discussed.

AdultMalemedicine.medical_specialtyScale (ratio)PsychometricsPsychometricsTest validitybehavioral disciplines and activitiesmental disordersmedicineHumansPsychiatryReliability (statistics)Psychiatric Status Rating ScalesPanic disorderPanicmedicine.diseaseAnxiety DisordersPanichumanitiesPsychiatry and Mental healthPhobic DisordersAnxietyFemalemedicine.symptomPsychologyArousalAgoraphobiaActa psychiatrica Scandinavica
researchProduct

Detached and distracted: ERP correlates of altered attentional function in depersonalisation.

2018

Abstract Depersonalisation (DP) is a psychological condition marked by feelings of disembodiment. In everyday life, it is frequently associated with concentration problems. The present study used visual event-related potentials (ERPs) in a Posner-type spatial cueing task with valid, invalid and spatially neutral cues to delineate the potential neurophysiological correlates of these concentration problems. Altered attentional functioning at early, sensory stages was found in DP patients but not in anxiety- and depression-matched psychosomatic patients without DP. Specifically, DP was associated with decreased suppression of stimuli at unattended locations, shown as absent processing costs fo…

AdultMalemedicine.medical_specialtySensory systemAudiologyElectroencephalography050105 experimental psychology03 medical and health sciences0302 clinical medicineCognitionmedicineReaction TimeVisual attentionHumans0501 psychology and cognitive sciencesAttentionEvoked PotentialsCued speechPsychiatric Status Rating Scalesmedicine.diagnostic_testGeneral Neuroscience05 social sciencesCognitionElectroencephalographyNeurophysiologyPsychophysiologic DisordersNeuropsychology and Physiological PsychologyDepersonalizationSpace PerceptionAnxietyFemalemedicine.symptomCuesPsychology030217 neurology & neurosurgeryPsychomotor PerformanceBiological psychology
researchProduct

The benefit from whole body acupuncture in major depression.

2000

Background: In a single-blind placebo-controlled study design we investigated the efficacy of acupuncture additionally applied to drug treatment in major depression. Methods: We randomly included 70 inpatients with a major depressive episode in three different treatment groups: verum acupuncture, placebo acupuncture and a control group. All three groups were pharmacologically treated with the antidepressant mianserin. The verum group received acupuncture at specific points considered effective in the treatment of depression. The placebo group was treated with acupuncture at non-specific locations and the control group received pharmacological treatment plus clinical management. Acupuncture …

AdultMalemedicine.medical_specialtyTime FactorsAcupuncture TherapyMianserinPlaceboSeverity of Illness Indexlaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessAcupunctureMedicineHumansSingle-Blind MethodMajor depressive episodeAgedPsychiatric Status Rating ScalesDepressive Disorder MajorDiazepambusiness.industryMiddle AgedMianserinSurgeryClinical trialPsychiatry and Mental healthClinical PsychologyCross-Sectional StudiesTreatment OutcomeAnti-Anxiety AgentsAntidepressive Agents Second-GenerationFemalemedicine.symptombusinessPsychopathologymedicine.drugJournal of affective disorders
researchProduct

Course of cognitive deficits in first episode of non-affective psychosis: a 3-year follow-up study.

2013

Abstract Cognitive dysfunctions are critical determinants of the quality of life and functionality in schizophrenia. Whether the cognitive deficits present at an early stage, are static or change across one's lifespan is still under debate. This study aims to investigate the long-term (3 years) course of cognitive deficits in a large and representative cohort of first episode schizophrenia spectrum patients (N = 155),and evaluate their influence on disability. In addition, a healthy control sample (N = 43) was also studied for comparison. This study evaluates the performance of patients and controls in a battery of cognitive assessments using baseline, 1-year and 3-year follow-up designs. T…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentNeuropsychological TestsCohort StudiesYoung AdultVisual memorymedicineHumansSpectrum disorderEffects of sleep deprivation on cognitive performanceCognitive declinePsychiatryEpisodic memoryBiological PsychiatryAgedFirst episodePsychiatric Status Rating ScalesAnalysis of VarianceCognitionMiddle AgedVerbal Learningmedicine.diseasePsychiatry and Mental healthSchizophreniaDisease ProgressionSchizophreniaFemaleSchizophrenic PsychologyPsychologyCognition DisordersClinical psychologySchizophrenia research
researchProduct

Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study

2011

Preventing relapse during the first years of illness has a critical impact on lifelong outcomes in schizophrenia. A better understanding and improvement in factors which influence relapse should diminish the risk of relapse and consequently improve the outcome of the illness.To identify factors associated with relapse after 3 years of a first episode in a sample of non-affective psychosis patients who are representative of clinical practice in an epidemiological catchment.We analyzed socio-demographic and clinical data from a cohort of patients who were treated in a specialized early intervention service and who were at risk of relapse during a 3-year follow-up. Univariate analyses, logisti…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentYoung AdultCatchment Area HealthPredictive Value of TestsInternal medicineEpidemiologySecondary PreventionmedicineHumansLongitudinal StudiesFamily historyPsychiatryBiological PsychiatryProportional Hazards ModelsRetrospective StudiesPsychiatric Status Rating ScalesFirst episodeUnivariate analysisProportional hazards modelHazard ratioRetrospective cohort studyMiddle AgedSurvival AnalysisPsychiatry and Mental healthLogistic ModelsPsychotic DisordersCohortFemalePsychologyAntipsychotic AgentsJournal of Psychiatric Research
researchProduct

Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients

2010

To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions.Two hundred and eighty inpatients with schizophrenia (DSM-IV criteria) were assessed with the Positive and Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the symptom-severity component of the consensus criteria (Remission in Schizophrenia Working Group) as a rating of three or less in the relevant PANSS items at discharge, and response as a reduction of at least 20% in the PANSS total score from admission to discharge.The mean duration of in…

AdultMalemedicine.medical_specialtyTime FactorsAntipsychotic treatmentSeverity of Illness IndexYoung Adult03 medical and health sciences0302 clinical medicineNaturalistic observationInternal medicineOutcome Assessment Health CareSeverity of illnessmedicineHumansYoung adultPsychiatryBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleRetrospective cohort studyMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthSchizophreniaTime courseSchizophreniaRegression AnalysisFemalePsychology030217 neurology & neurosurgeryAntipsychotic AgentsSchizophrenia Research
researchProduct

Individual music therapy for depression: randomised controlled trial

2011

BackgroundMusic therapy has previously been found to be effective in the treatment of depression but the studies have been methodologically insufficient and lacking in clarity about the clinical model employed.AimsTo determine the efficacy of music therapy added to standard care compared with standard care only in the treatment of depression among working-age people.MethodParticipants (n= 79) with an ICD–10 diagnosis of depression were randomised to receive individual music therapy plus standard care (20 bi-weekly sessions) or standard care only, and followed up at baseline, at 3 months (after intervention) and at 6 months. Clinical measures included depression, anxiety, general functioning…

AdultMalemedicine.medical_specialtyTime FactorsMusic therapyAdolescentAnxietySeverity of Illness Indexlaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Randomized controlled triallawSeverity of illnessmedicineHumansAffective Symptoms030212 general & internal medicinePsychiatryMusic TherapyFinlandDepression (differential diagnoses)ta515Psychiatric Status Rating ScalesDepressive DisorderIntention-to-treat analysisOdds ratioMiddle Agedta3124Intention to Treat Analysis030227 psychiatryPsychiatry and Mental healthOutcome and Process Assessment Health Careta6131Quality of LifePhysical therapyPsychotherapy BriefAnxietyFemalemedicine.symptomPsychologyProgram EvaluationThe British Journal of Psychiatry
researchProduct

Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression

2009

Abstract Background There is substantial evidence that early improvement (EI) under antidepressant treatment is a clinically useful predictor of later treatment outcome in patients with major depressive disorders. The aim of this study was to test whether EI can also be used as a predictor for treatment outcome in patients with mild major, minor or subsyndromal depression, i.e. patients, who are typically treated by general practitioners. Methods Analyses were carried out using data from 223 patients of a 10-weeks randomized, placebo-controlled trial comparing the effectiveness of sertraline and cognitive-behavioural therapy (CBT) in patients with mild major, minor or subsyndromal depressio…

AdultMalemedicine.medical_specialtyTime FactorsSeverity of Illness Indexlaw.inventionRandomized controlled trialPredictive Value of TestslawSertralineSurveys and QuestionnairesInternal medicineSeverity of illnessmedicineHumansProspective StudiesPsychiatryProspective cohort studyDepression (differential diagnoses)Depressive DisorderDepressive Disorder MajorSertralineCognitive Behavioral TherapyHamilton Rating Scale for DepressionCombined Modality TherapyAntidepressive AgentsConfidence intervalPsychiatry and Mental healthClinical PsychologyTreatment OutcomePredictive value of testsFemalePsychologymedicine.drugJournal of Affective Disorders
researchProduct